Behind the Science: Behind JAK Inhibitor Box Warnings

In this interview, we explore how the FDA box warning given to certain JAK inhibitors after study results on tofacitinib were released. We talked to multiple dermatologists about their thoughts on this warning. We wanted to know how this will affect the drug pipeline, and how dermatologists should explain the situation to their patients.